Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BIONET Corp. (1784.TWO)
Taipei, TW
Established in 1989 and headquartered in Taipei City, Taiwan, BIONET Corp. is a global leader in umbilical cord blood preservation, serving clients across Taiwan and internationally. The company provides a comprehensive suite of stem cell banking services, encompassing the storage of general stem cells, mesenchymal stem cells, dental stem cells, adipose stem cells, and peripheral blood stem cells combined with immune cells. Beyond its core stem cell preservation, BIONET also conducts genetic testing services. Its product offerings further extend to anti-aging solutions leveraging stem cell technology, alongside its unique ANIKINE series. Additionally, the company is a pioneer in offering Exosome, an innovative cell-free therapeutic approach.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.93% | -6.45% | -11.66% | -35.87% | -34.29% | -35.56% | -4.03% | +16.14% | +76.60% | +143.79% | +264.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+1.2% Q1'26: +8.2% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-38.2% Q1'26: -16.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+6.6% Q1'26: +8.2% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+1.2% Q1'26: -1.6% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+0.9% Q1'26: -1.4% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-98.4% ★ Q1'26: -109.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×8.04× ★ Q1'26: -6.44× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
921.42M
est: 986.00M (-6.5%)
|
980.38M
est: 996.00M (-1.6%)
|
1.13B
est: 1.24B (-9.0%)
|
1.22B
est: 1.22B (+0.2%)
|
1.24B
est: 1.33B (-7.2%)
|
1.33B
1.33B – 1.33B
+0.0% YoY
|
| EBITDA |
80.41M
est: 100.88M (-20.3%)
|
113.97M
est: 101.90M (+11.8%)
|
147.10M
est: 126.77M (+16.0%)
|
149.09M
est: 114.12M (+30.6%)
|
14.47M
est: 124.69M (-88.4%)
|
124.69M
124.69M – 124.69M
+0.0% YoY
|
| EBIT |
41.58M
est: 60.32M (-31.1%)
|
70.91M
est: 60.93M (+16.4%)
|
107.49M
est: 75.80M (+41.8%)
|
103.52M
est: 75.45M (+37.2%)
|
14.47M
est: 82.44M (-82.5%)
|
82.44M
82.44M – 82.44M
+0.0% YoY
|
| Net Income |
26.62M
est: 46.05M (-42.2%)
|
37.97M
est: 52.22M (-27.3%)
|
78.40M
est: 90.67M (-13.5%)
|
83.70M
est: 1.17M (+7,043.6%)
|
848.0K
est: 1.45M (-41.7%)
|
1.45M
1.45M – 1.45M
+0.0% YoY
|
| SGA |
385.97M
est: 403.92M (-4.4%)
|
391.95M
est: 408.02M (-3.9%)
|
433.23M
est: 507.57M (-14.6%)
|
483.75M
est: 390.12M (+24.0%)
|
—
est: 426.25M (-100.0%)
|
426.25M
426.25M – 426.25M
+0.0% YoY
|
| EPS |
0.56
est: 0.91 (-38.2%)
|
0.80
est: 1.03 (-22.1%)
|
1.55
est: 1.78 (-13.1%)
|
1.65
est: 1.41 (+17.0%)
|
1.02
est: 1.75 (-41.7%)
|
1.75
1.75 – 1.75
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 34.8K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 30.3K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mei Hua Lai | Vice President of Administrative Office | — | — |
| Qianyu Liu | Accounting Supervisor | — | — |
| Qing Yuan Kang | General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1784.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
